Combination immunotherapy strategies for glioblastoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11060-020-03481-0.pdf
Reference65 articles.
1. Burki TK (2015) pembrolizumab for patients with advanced melanoma. Lancet Oncol 16(6):e264. https://doi.org/10.1016/S1470-2045(15)70193-2
2. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546. https://doi.org/10.1056/NEJMoa1910836
3. Garon EB, Rizvi NA, Hui R et al (2015) pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824
4. Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413. https://doi.org/10.1126/science.aan6733
5. Jackson CM, Choi J, Lim M (2019) Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol 20(9):1100–1109. https://doi.org/10.1038/s41590-019-0433-y
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. GBM immunotherapy: Exploring molecular and clinical frontiers;Life Sciences;2024-11
2. Oncolytic virotherapy improves immunotherapies targeting cancer stemness in glioblastoma;Biochimica et Biophysica Acta (BBA) - General Subjects;2024-09
3. Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology‐based strategies for enhanced CAR T/NK cell therapy;Bioengineering & Translational Medicine;2024-08-31
4. Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy;International Journal of Nanomedicine;2024-06
5. Identification and validation of drugs for repurposing in Glioblastoma: a computational and experimental workflow;2024-05-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3